EXPE vs XERS · P/E 20, rev $7.74B vs rev $175.2M
Expedia Group Inc. (EXPE) versus Xeris Pharmaceuticals Inc (XERS) — a side-by-side from cached financials, not a winner call.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on US.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Latest reported XERS revenue for 2026-06-30 was $175.2M. Net income was -$28.9M. XERS currently screens at market cap $760.7M.
EXPE currently screens at market cap $21.71B and trailing P/E 20.4. XERS currently screens at market cap $760.7M.
Not investment advice. Open the EXPE and XERS stock pages for the full models.
Not investment advice.